NASDAQ:NEUP Neuphoria Therapeutics (NEUP) Stock Price, News & Analysis $3.92 -0.01 (-0.13%) As of 02:32 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Neuphoria Therapeutics Stock (NASDAQ:NEUP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Neuphoria Therapeutics alerts:Sign Up Key Stats Today's Range$3.88▼$3.9850-Day Range$3.30▼$5.4652-Week Range$3.19▼$21.40Volume27,238 shsAverage Volume111,272 shsMarket Capitalization$21.20 millionP/E RatioN/ADividend YieldN/APrice Target$21.00Consensus RatingHold Company Overview Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA. Read More Neuphoria Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreNEUP MarketRank™: Neuphoria Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 594th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingNeuphoria Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 1 sell rating.Upside PotentialNeuphoria Therapeutics has a consensus price target of $21.00, representing about 433.0% upside from its current price of $3.94.Amount of Analyst CoverageNeuphoria Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Neuphoria Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Neuphoria Therapeutics are expected to grow in the coming year, from ($4.07) to ($2.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neuphoria Therapeutics is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neuphoria Therapeutics is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuphoria Therapeutics has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Neuphoria Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.29% of the float of Neuphoria Therapeutics has been sold short.Short Interest Ratio / Days to CoverNeuphoria Therapeutics has a short interest ratio ("days to cover") of 0.14, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neuphoria Therapeutics has recently decreased by 3.14%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeuphoria Therapeutics does not currently pay a dividend.Dividend GrowthNeuphoria Therapeutics does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Neuphoria Therapeutics this week, compared to 2 articles on an average week. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Neuphoria Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders1.50% of the stock of Neuphoria Therapeutics is held by insiders.Percentage Held by Institutions15.90% of the stock of Neuphoria Therapeutics is held by institutions.Read more about Neuphoria Therapeutics' insider trading history. Receive NEUP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuphoria Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NEUP Stock News HeadlinesThe M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—NRIM, NEUP, SAFT, and RMAXJuly 30, 2026 | globenewswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—PBCO, NEUP, SAFT, and PFLCJuly 28, 2026 | globenewswire.com[URGENT] Mode Mobile terms changing Aug 14Mode Mobile has secured its Nasdaq ticker, $MODE, while still in the pre-IPO stage. More than 60,000 investors have already put over $100 million into the company, including original Shark Tank investor Kevin Harrington. The company reports 490M+ users, $115M+ in lifetime revenue, and $1B+ earned and saved by users across 170+ countries. Deloitte ranked Mode North America's #1 fastest-growing software company in 2023 after 32,481% growth. Pre-IPO shares are currently priced at 0.52 dollars, but that price is set to change on August 14.August 4 at 1:00 AM | Mode Mobile (Ad)Wall Street Zen Upgrades Neuphoria Therapeutics (NASDAQ:NEUP) to HoldJuly 25, 2026 | americanbankingnews.comNEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its ShareholdersJuly 24, 2026 | businesswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP)July 24, 2026 | prnewswire.comSmall cap movers: Scancell heads to Nasdaq as AIM's headcount falls to 612July 24, 2026 | msn.comScancell and Neuphoria agree all-share merger supported by up to US$89 million financingJuly 24, 2026 | uk.finance.yahoo.comSee More Headlines NEUP Stock Analysis - Frequently Asked Questions How have NEUP shares performed this year? Neuphoria Therapeutics' stock was trading at $3.88 on January 1st, 2026. Since then, NEUP shares have increased by 1.5% and is now trading at $3.94. How were Neuphoria Therapeutics' earnings last quarter? Neuphoria Therapeutics Inc. (NASDAQ:NEUP) posted its earnings results on Friday, May, 15th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.47. How do I buy shares of Neuphoria Therapeutics? Shares of NEUP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/15/2026Today8/04/2026Next Earnings (Estimated)9/02/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (9m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 NEUP's financial health is in the Yellow zone, according to TradeSmith. NEUP has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NEUP Previous SymbolNASDAQ:NEUP CIK1191070 Webwww.bionomics.com.au Phone61-8-8150-7400FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Neuphoria Therapeutics$21.00 High Price Target$35.00 Low Price Target$7.00 Potential Upside/Downside+435.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($11.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$370 thousand Net MarginsN/A Pretax Margin-40.58% Return on Equity-76.93% Return on Assets-54.76% Debt Debt-to-Equity RatioN/A Current Ratio14.31 Quick Ratio14.31 Sales & Book Value Annual Sales$15.65 million Price / Sales1.35 Cash Flow$0.16 per share Price / Cash Flow24.90 Book Value$10.11 per share Price / Book0.39Miscellaneous Outstanding Shares5,400,000Free Float5,324,000Market Cap$21.19 million OptionableN/A Beta0.75 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:NEUP) was last updated on 8/4/2026 by MarketBeat.com Staff. From Our PartnersA Wall Street Veteran's Weekly Trade for Any Market ConditionDave Aquino spent 25 years at Merrill Lynch and Vanguard studying one weekly options play that worked in bull,...Base Camp Trading | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored1 Stock to Own by July 31stA scheduled announcement on July 31st could reshuffle the stock market's winners and losers - and one lesser-k...Chaikin Analytics | SponsoredHe bet half his $9 billion on ONE stockOne of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund ...Stansberry Research | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredNvidia's CEO says this small device is critical for AI growthA tiny glass device smaller than a fingertip could redefine AI hardware. Nvidia CEO Jensen Huang calls it esse...Brownstone Research | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuphoria Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuphoria Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NEUP Stock Alerts